Harvard Bioscience (HBIO) Change in Receivables (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Change in Receivables of -$1.4 million for Q1 2026, up 2.23% year-over-year from -$1.4 million in Q1 2025, and down 135.54% quarter-over-quarter from $4.0 million in Q4 2025.
Harvard Bioscience (HBIO) Change in Receivables (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Change in Receivables for 17 consecutive years, with -$1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 2.23% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at $966000.0 (up 156.56% YoY), while the FY2025 annual figure was $934000.0, up 195.89% from the prior year.
- Change in Receivables slipped to -$1.4 million in Q1 2026 per HBIO's latest filing, from $4.0 million in the prior quarter.
- Across five years, Change in Receivables topped out at $4.0 million in Q4 2025 and bottomed at -$2.8 million in Q2 2024.
- Historically, Change in Receivables has averaged -$413882.4 across 5 years, with a median of -$855000.0 in 2023.
- Annual changes were most pronounced in 2022 — Change in Receivables tumbled 897.32% — and 2023, when it jumped 161.29%.
- Harvard Bioscience's Change in Receivables stood at $1.3 million in 2022, then dropped by 26.48% to $941000.0 in 2023, then surged by 147.5% to $2.3 million in 2024, then soared by 69.86% to $4.0 million in 2025, then slumped by 135.54% to -$1.4 million in 2026.
- Business Quant data shows HBIO's Change in Receivables at -$1.4 million in Q1 2026, $4.0 million in Q4 2025, and $210000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 74.90 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | - |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 37.21 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 2.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | - |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 252.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | - |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 156.00 Mn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn | -58,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58,000.00 |
| Jun 30, 2026 | -58,000.00 |
| Mar 31, 2026 | -1.41 Mn |
| Mar 31, 2026 | -1.41 Mn |
| Dec 31, 2025 | 3.96 Mn |
| Dec 31, 2025 | 3.96 Mn |
| Sep 30, 2025 | 210,000.00 |
| Sep 30, 2025 | 210,000.00 |
| Jun 30, 2025 | -1.79 Mn |
| Jun 30, 2025 | -1.79 Mn |
| Mar 31, 2025 | -1.44 Mn |
| Mar 31, 2025 | -1.44 Mn |
| Dec 31, 2024 | 2.33 Mn |
| Dec 31, 2024 | 2.33 Mn |
| Sep 30, 2024 | 155,000.00 |
| Sep 30, 2024 | 155,000.00 |
| Jun 30, 2024 | -2.75 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Mar 31, 2024 | -704,000.00 |
| Mar 31, 2024 | -704,000.00 |